Literature DB >> 10714620

Clinical issues in long-term treatment with antidepressants.

J M Zajecka1.   

Abstract

Historically, the emphasis in treating depression has been focused on the acute phase of treatment, with few published data on the continuation and maintenance phases of treatment. Yet the risk of depression increases with each episode, with a 50% to 90% chance of developing another episode after 1 or 2 prior episodes of depression. Moreover, subsequent episodes of depression are often of longer duration, more severe, and less responsive to treatment. Most patients with major depression require some form of long-term antidepressant treatment, and many need lifelong treatment. Optimizing efficacy and minimizing side effects are essential during both the acute and long-term phases of antidepressant treatment. Antidepressant side effects, including insomnia or somnolence, weight gain, asthenia, and sexual dysfunction, can significantly decrease patient compliance with long-term treatment for depression. Identification and management of side effects, combined with early and ongoing educational messages to the patient about treatment issues and the importance of sustaining illness remission, help improve compliance and reduce the potential for premature discontinuation of an otherwise optimal antidepressant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714620

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.

Authors:  Julia Zaccarelli-Magalhães; André Rinaldi Fukushima; Natalia Moreira; Marianna Manes; Gabriel Ramos de Abreu; Esther Lopes Ricci; Paula A Faria Waziry; Helenice de Souza Spinosa
Journal:  Pharmacol Rep       Date:  2019-12-20       Impact factor: 3.024

2.  Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.

Authors:  Adam Keller Ashton; Brenda D Jamerson; Wendy L Weinstein; Christine Wagoner
Journal:  Curr Ther Res Clin Exp       Date:  2005-03

3.  Desvenlafaxine and weight change in major depressive disorder.

Authors:  Karen A Tourian; Claire Leurent; Jay Graepel; Philip T Ninan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.

Authors:  Michael J Thorpy; Jonathan R L Schwartz; Ruzica Kovacevic-Ristanovic; Roza Hayduk
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

5.  A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.

Authors:  Karen A Tourian; Bruno Pitrosky; S Krishna Padmanabhan; Gregory R Rosas
Journal:  Prim Care Companion CNS Disord       Date:  2011

6.  Low-Frequency Sonophoresis as an Active Approach to Potentiate the Transdermal Delivery of Agomelatine-Loaded Novasomes: Design, Optimization, and Pharmacokinetic Profiling in Rabbits.

Authors:  Mai Ahmed Tawfik; Magdy Ibrahim Mohamed; Mina Ibrahim Tadros; Sara Nageeb El-Helaly
Journal:  AAPS PharmSciTech       Date:  2021-10-27       Impact factor: 3.246

7.  Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study.

Authors:  Charlene Bryan; Thomas Songer; Maria Mori Brooks; Michael E Thase; Bradley Gaynes; Michael Klinkman; G K Balasubramani; A John Rush; Madhukar H Trivedi; Maurizio Fava; Stephen R Wisniewski
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Sexual function in postpartum women treated for depression: results from a randomized trial of nortriptyline versus sertraline.

Authors:  Teresa Lanza di Scalea; Barbara H Hanusa; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2009-03-09       Impact factor: 4.384

9.  Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study.

Authors:  H J Cho; M Kivimäki; J E Bower; M R Irwin
Journal:  Psychol Med       Date:  2012-11-14       Impact factor: 7.723

10.  Role of repetitive transcranial magnetic stimulation in maintenance treatment of resistant depression.

Authors:  Biswadip Chatterjee; Nand Kumar; Shailesh Jha
Journal:  Indian J Psychol Med       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.